Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
The estimated enrollment duration is approximately 2 years, while duration of observation is approximately 5 years.
Study Type
OBSERVATIONAL
Enrollment
266
Blood samples obtained for biomarker analyses
Cheek swab obtained for genetic analysis
Biomarker identification: Demographics
Identification of biomarkers associated with demographic characteristics
Time frame: Baseline
Biomarker identification: Baseline disease characteristics
Identification of biomarkers associated with disease characteristics at study entry (eg, disease severity, presence of other co-morbidities)
Time frame: Baseline
Biomarker identification: Changes in disease severity
Identification of biomarkers associated with disease severity increases/decreases (including remission) over time
Time frame: Up to 5 years
Biomarker evaluation: High versus low disease severity across participants
Examination of biomarker expression in participants with high disease severity versus those with low disease severity
Time frame: Up to 5 years
Biomarker identification: New presentation or resolution of atopic comorbidity
Identification of biomarkers associated with onset of a new atopic comorbidity or resolution of an existing atopic comorbidity
Time frame: Up to 5 years
Biomarker identification: Introduction of new systemic treatment
Identification of biomarkers associated with introduction of new systemic treatment
Time frame: Up to 5 years
Biomarker identification: Response to systemic treatment
Identification of biomarkers associated with response to systemic treatment
Time frame: Up to 5 years
Biomarker identification: Loss of response to systemic treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
C Squared Research Center Site Number : 8400068
Birmingham, Alabama, United States
Cahaba Dermatology Site Number : 8400046
Birmingham, Alabama, United States
C2 Research Center, LLC Site Number : 8400071
Montgomery, Alabama, United States
Axis Clinical Trials Site Number : 8400025
Los Angeles, California, United States
Madera Family Medical Group Site Number : 8400054
Madera, California, United States
Fomat Medical Research, Inc. Site Number : 8400033
Oxnard, California, United States
Amedica Research Institute, Inc. Site Number : 8400067
Hialeah, Florida, United States
Eastern Research, Inc. Site Number : 8400032
Hialeah, Florida, United States
Vista Health Research, LLC Site Number : 8400034
Miami, Florida, United States
Pediatric & Adult Research Center Site Number : 8400040
Orlando, Florida, United States
...and 38 more locations
Identification of biomarkers associated with loss of response to systemic treatment
Time frame: Up to 5 years
Biomarker evaluation: Start of systemic therapy early in life versus later in life
Examination of whether biomarker expression in participants who started systemic therapy for AD early in life (within 6 months) differs from those who started it later in life
Time frame: Up to 5 years